Newsletter - March 03, 2016
Priority Review Vouchers and FDA: Agency Complains of Increased Work
A recent GAO report on the public support for the Priority Review Voucher (PRV) program presents a mixed picture where the industry loves the program and wants it to be maintained while the FDA has an exactly opposite opinion. PRVs have been around for about 7 years since the first PRV program was implemented in 2007 with great fanfare. Read More..
Use FDA’s Processes to Speed US Patient Access to Cuban Lung Cancer Vaccine
Medical researchers in Cuba invented a vaccine, called CimaVax-EGF, for lung cancer. CimaVax has been tested in about 7 well-designed clinical trials in patients with advanced non-small-cell lung cancer (NSCLC), and used to treat about 5000 patients over the last 2 decades. This one of a kind vaccine costs about $1 per shot and patients need to take one shot every month. Compare that to the 11 drugs approved by FDA.. Read More..
Priority Review Vouchers and FDA: Agency Complains of Increased Work
A recent GAO report on the public support for the Priority Review Voucher (PRV) program presents a mixed picture where the industry loves the program and wants it to be maintained while the FDA has an exactly opposite opinion. PRVs have been around for about 7 years since the first PRV program was implemented in 2007 with great fanfare. Read More..
Use FDA’s Processes to Speed US Patient Access to Cuban Lung Cancer Vaccine
Medical researchers in Cuba invented a vaccine, called CimaVax-EGF, for lung cancer. CimaVax has been tested in about 7 well-designed clinical trials in patients with advanced non-small-cell lung cancer (NSCLC), and used to treat about 5000 patients over the last 2 decades. This one of a kind vaccine costs about $1 per shot and patients need to take one shot every month. Compare that to the 11 drugs approved by FDA.. Read More..
